LCS-1

LCS-1 is a potent and selective small-molecule inhibitor of **Superoxide dismutase 1 (SOD1)**. It is primarily utilized as a research tool and preclinical candidate to investigate therapeutic vulnerabilities in cancers characterized by high SOD1 expression, such as **Malignant Transformation of Ovarian Teratoma (MTMCT)** and certain squamous cell carcinomas. By inhibiting the enzymatic activity of SOD1, LCS-1 prevents the dismutation of superoxide radicals, leading to an accumulation of reactive oxygen species (ROS). This induction of oxidative stress results in DNA damage (marked by γH2AX), cell cycle impairment, and the activation of apoptotic pathways (marked by cleaved caspase-3). Preclinical studies have demonstrated that oral administration of LCS-1 can significantly suppress tumor growth in patient-derived xenograft models, suggesting its potential as a redox-modulating therapeutic strategy for chemoresistant malignancies.

Other names

4,5-dichloro-2-(3-methylphenyl)pyridazin-3-one4,5-dichloro-2-(m-tolyl)pyridazin-3(2H)-one4,5-dichloro-2-(3-methylphenyl)-3(2H)-pyridazinone